Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariate and multivariate Cox regression analysis of the gene signature and overall survival of NSCLC patients

From: A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer

Variables Patients
(N)
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
GSE31210
 Age ≤ 65/> 65 176/50 2.58 (1.31–5.08) 5.99E−03 3.51 (1.72–7.15) 5.44E−04
 Gender Female/male 121/105 1.52 (0.78–2.96) 2.19E−01   
 ALK fusion +/− 215/11 1.49 (0.36–6.24) 5.82E−01   
 EGFR mutation +/− 99/127 0.47 (0.24–0.93) 2.96E−02 1.87 (0.65–5.37) 2.47E−01
 KRAS mutation +/− 206/20 0.87 (0.27–2.85) 8.17E−01   
 Triple negative No/yes 158/68 2.19 (1.12–4.26) 2.12E−02 2.95 (1.06–8.19) 3.76E−02
 Myc copy Low/high 207/17 0.7 (0.17–2.9) 6.18E−01   
 Stage I/II 168/58 4.23 (2.17–8.24) 2.17E−05 3.45 (1.72–6.93) 5.06E−04
 Smoking No/yes 115/111 1.64 (0.84–3.2) 1.50E−01   
 Risk score Low/high 129/97 6.14 (2.68–14.07) 1.84E−05 5.47 (2.3–12.99) 1.21E−04
GSE37745
 Age ≤ 65/> 65 102/94 1.35 (0.98–1.88) 6.88E−02   
 Gender Female/male 89/107 1.1 (0.79–1.52) 5.85E−01   
 Stage I/II 130/35 1.22 (0.79–1.87) 3.66E−01 1.14 (0.73–1.77) 5.68E−01
 Stage I/III 130/27 1.86 (1.19–2.93) 6.88E−03 1.63 (1.02–2.63) 4.27E−02
 Stage I/IV 130/4 1.31 (0.42–4.15) 6.43E−01 1.97 (0.61–6.35) 2.57E−01
 Histological type Adeno/large 106/24 0.89 (0.52–1.53) 6.75E−01   
 Histological type Adeno/squamous 106/66 1.26 (0.88–1.79) 2.05E−01   
 WHO performance status 0/1 105/75 1.91 (1.35–2.7) 2.38E−04 1.96 (1.39–2.79) 1.53E−04
 WHO performance status 0/2 105/12 1.95 (1.01–3.79) 4.83E−02 1.81 (0.92–3.57) 8.66E−02
 WHO performance status 0/3 105/4 1.13 (0.36–3.61) 8.32E−01 1.09 (0.34–3.54) 8.80E−01
 Risk score Low/high 97/99 1.56 (1.12–2.16) 8.31E−03 1.44 (1.02–2.04) 3.80E−02
GSE50081
 Age ≤ 65/> 65 59/122 1.56 (0.93–2.61) 9.04E−02   
 Gender Female/male 83/98 1.93 (1.19–3.14) 7.80E−03 2 (1.23–3.26) 5.47E−03
 Stage I/II 127/54 1.69 (1.05–2.72) 3.10E−02 1.63 (1.01–2.63) 4.71E−02
 Histological type Adeno/large 127/7 1.71 (0.62–4.74) 3.01E−01   
 Histological type Adeno/squamous 127/43 1.84 (0.57–5.92) 3.03E−01   
 Histological type Adeno/other 127/4 0.8 (0.46–1.39) 4.35E−01   
 Smoking No/yes 24/136 1.39 (0.66–2.92) 3.89E−01   
 Risk score Low/high 79/102 2.21 (1.34–3.64) 1.81E−03 2.09 (1.27–3.45) 3.91E−03
All patients
 Age ≤ 65/> 65 337/266 1.92 (1.5–2.46) 2.48E−07 1.83 (1.42–2.35) 2.94E−06
 Gender Female/male 293/310 1.45 (1.13–1.86) 3.79E−03 1.27 (0.98–1.64) 7.14E−02
 Stage I/II 425/147 1.67 (1.26–2.21) 3.43E−04 1.5 (1.13–2) 5.31E−03
 Stage I/III 425/27 3.6 (2.34–5.56) 7.02E−09 2.79 (1.79–4.36) 6.58E−06
 Stage I/IV 425/4 2.53 (0.81–7.93) 1.12E−01 3.23 (1.02–10.23) 4.58E−02
 Histological type Adeno/large 459/31 1.76 (1.1–2.81) 1.83E−02 1.51 (0.94–2.43) 9.16E−02
 Histological type Adeno/squamous 459/109 2.29 (0.73–7.18) 1.56E−01 1.92 (0.6–6.1) 2.70E−01
 Histological type Adeno/other 459/4 1.85 (1.39–2.45) 2.09E−05 1.27 (0.94–1.72) 1.18E−01
 Risk score Low/high 305/298 2.11 (1.63–2.72) 1.03E−08 1.65 (1.26–2.18) 3.32E−04
  1. HR: hazard ratio; CI: confidence interval; Adeno: adenocarcinoma; Large: large cell carcinoma; Squamous: squamous cell carcinoma